John Breton

1.7k citations

35 papers · 889 indexed · 1 hit paper · h-index 17

Impact in

Pharmacology top 10%
- Inflammatory mediators and NSAID effects
Organic Chemistry top 10%
- Synthesis and biological activity
- Multicomponent Synthesis of Heterocycles

Papers in ⓘ

Pharmacology 11
- Inflammatory mediators and NSAID effects 8
- Antibiotics Pharmacokinetics and Efficacy 3
Molecular Biology 10
- Natural product bioactivities and synthesis 4

Co-authors: Marie Chabot‐Fletcher (15 shared papers)Don E. Griswold (7 shared papers)Jerry L. Adams (5 shared papers)John C. Lee (3 shared papers)Margaret E. Sorenson (4 shared papers)Ravi S. Garigipati (4 shared papers)Edward F. Webb (4 shared papers)Jeffrey T. Laydon (3 shared papers)
Journals: Journal of Investigative Dermatology (3 papers)Antimicrobial Agents and Chemotherapy (3 papers)Journal of Pharmacology and Experimental Therapeutics (2 papers)Biochemical Journal (2 papers)Biochemical Pharmacology (2 papers)
Partner nations: United States United Kingdom Colombia

In The Last Decade

John Breton

33 papers receiving 846 citations

Hit Papers

align trajectories log scale

Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials 2024 · 44 citations

Peers

Countries citing papers authored by John Breton

Since Specialization

Citations

This map shows the geographic impact of John Breton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Breton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Breton more than expected).

Fields of papers citing papers by John Breton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Breton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Breton. The network helps show where John Breton may publish in the future.

Co-authors

The 25 scholars most cited alongside John Breton, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John Breton Line = papers co-authored together John Breton links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 35 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	2,4,5- triarylimidazole inhibitors of IL-1 biosynthesis Bioorganic & Medicinal Chemistry Letters ·Timothy F. Gallagher, Susan M. Fier-Thompson, Ravi S. Garigipati, Margaret E. Sorenson, Juanita M. Smietana, Dennis Lee, Paul E. Bender, John C. Lee, Jeffrey T. Laydon, Don E. Griswold, Marie Chabot‐Fletcher, John Breton, Jerry L. Adams	1995	119
2	1-Substituted 4-Aryl-5-pyridinylimidazoles: A New Class of Cytokine Suppressive Drugs with Low 5-Lipoxygenase and Cyclooxygenase Inhibitory Potency Journal of Medicinal Chemistry ·Jeffrey C. Boehm, Juanita M. Smietana, Margaret E. Sorenson, Ravi S. Garigipati, Timothy F. Gallagher, Peter L. Sheldrake, Jeremy N. Bradbeer, Alison M. Badger, Jeffrey T. Laydon, John C. Lee, Leonard M. Hillegass, D.E. Griswold, John Breton, Marie Chabot‐Fletcher, Jerry L. Adams	1996	97
3	Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis Scientific Reports ·C. Meurot, C. Martin, L. Sudre, John Breton, Carole Bougault, Révital Rattenbach, Keren Bismuth, C. Jacques, Francis Bérenbaum	2022	78
4	Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response Inflammation ·Don E. Griswold, Edward F. Webb, John Breton, John R. White, Paul Marshall, Theodore J. Torphy	1993	72
5	The natural product hymenialdisine inhibits interleukin-8 production in U937 cells by inhibition of nuclear factor-kappaB. PubMed ·John Breton, Marie Chabot‐Fletcher	1997	50
6	Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity? Journal of Orthopaedic Translation ·C. Meurot, C. Jacques, C. Martin, L. Sudre, John Breton, Révital Rattenbach, Keren Bismuth, Francis Bérenbaum	2022	47
7	Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials The Lancet ·Florian Wagenlehner, Caroline Perry, Thomas M. Hooton, Nicole E. Scangarella-Oman, Helen Millns, Marcy Powell, Emily Jarvis, Jeremy Dennison, Amanda Sheets, Deborah Butler, John Breton, Salim Janmohamed Hit paper breakdown →	2024	44
8	Topical retapamulin ointment (1%, wt/wt) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: Results of a randomized controlled trial Journal of the American Academy of Dermatology ·Lawrence Charles Parish, Joseph L. Jorizzo, John Breton, Joseph William Hirman, Nicole Scangarella, Ribhi M. Shawar, Scott Matthew White	2006	43
9	Characterization of peptidyl boronic acid inhibitors of mammalian 20 S and 26 S proteasomes and their inhibition of proteasomes in cultured cells Biochemical Journal ·Robert C. Gardner, Stephen J. Assinder, Gary Christie, Grant Mason, Roger E. Markwell, Harry Wadsworth, Mark R. McLaughlin, Ron J. King, Marie Chabot‐Fletcher, John Breton, David Allsop, A. Jennifer Rivett	2000	43
10	Interleukin-8 Production Is Regulated by Protein Kinase C in Human Keratinocytes Journal of Investigative Dermatology ·Marie Chabot‐Fletcher, John Breton, John Lee, Peter R. Young, Don E. Griswold	1994	38
11	Efficacy and Safety of Pharmacokinetically Enhanced Amoxicillin-Clavulanate at 2,000/125 Milligrams Twice Daily for 5 Days versus Amoxicillin-Clavulanate at 875/125 Milligrams Twice Daily for 7 Days in the Treatment of Acute Exacerbations of Chronic Bronchitis Antimicrobial Agents and Chemotherapy ·Sanjay Sethi, John Breton, Brian Wynne	2004	31
12	Pharmacology of the pyrroloimidazole, SK&F 105809—I Biochemical Pharmacology ·Paul Marshall, Don E. Griswold, John Breton, Edward F. Webb, Leonard M. Hillegass, Henry M. Sarau, John F. Newton, John C. Lee, Paul E. Bender, Nabil Hanna	1991	31
13	Bicyclic N-Hydroxyurea Inhibitors of 5-Lipoxygenase: Pharmacodynamic, Pharmacokinetic, and in Vitro Metabolic Studies Characterizing N-Hydroxy-N-(2,3-dihydro-6-(phenylmethoxy)-3-benzofuranyl)urea Journal of Medicinal Chemistry ·Jerry L. Adams, Ravi S. Garigipati, Margaret E. Sorenson, Stanley J. Schmidt, William R. Brian, John F. Newton, Kathy A. Tyrrell, Eric Garver, L A Yodis, Marie Chabot‐Fletcher, Maritsa N. Tzimas, Edward F. Webb, John Breton, Don E. Griswold	1996	26
14	The Natural Product Hymenialdisine Inhibits Interleukin-8 Production in U937 Cells by Inhibition of Nuclear Factor-κB Journal of Pharmacology and Experimental Therapeutics ·John Breton, Marie Chabot‐Fletcher	1997	21
15	Human Keratinocytes Lack the Components to Produce Leukotriene B4 Journal of Investigative Dermatology ·John Breton, Deborah J. Woolf, Peter R. Young, Marie Chabot‐Fletcher	1996	20
16	Evaluation of the cutaneous anti-inflammatory activity of azaspiranes Inflammation Research ·Don E. Griswold, Leopoldo Martín, A M Badger, John Breton, Marie Chabot‐Fletcher	1998	17
17	Human Keratinocytes Possess an sn-2 Acylhydrolase that is Biochemically Similar to the U937-Derived 85-kDa Phospholipase A2 Journal of Investigative Dermatology ·Mark McCord, Marie Chabot‐Fletcher, John Breton, Lisa A. Marshall	1994	17
18	Pharmacological characterization of SB 202235, a potent and selective 5-lipoxygenase inhibitor: effects in models of allergic asthma. Journal of Pharmacology and Experimental Therapeutics ·Marie Chabot‐Fletcher, David C. Underwood, John Breton, Jerry L. Adams, A. Kagey-Sobotka, D.E. Griswold, Lisa A. Marshall, Henry M. Sarau, Julia Winkler, Douglas W.P. Hay	1995	12
19	Effect of Staurosporine on Transcription Factor NF-κB in Human Keratinocytes Biochemical Pharmacology ·Marie Chabot‐Fletcher, John Breton	1998	10
20	Use of a continous assay of oxygen consumption to evaluate the pharmacology of 5-lipoxygenase inhibitors Prostaglandins Leukotrienes and Essential Fatty Acids ·John Breton, Paul M. Keller, Marie Chabot‐Fletcher, Leonard M. Hillegass, Walter E. DeWolf, D.E. Griswold	1993	9

About John Breton

John Breton is a scholar working on Pharmacology, Molecular Biology, Immunology, Oncology and Epidemiology, having authored 35 papers that have together received 889 indexed citations. Recurring topics across this work include Inflammatory mediators and NSAID effects (8 papers), Urinary Tract Infections Management (5 papers), Cytokine Signaling Pathways and Interactions (4 papers), Natural product bioactivities and synthesis (4 papers), Asthma and respiratory diseases (4 papers), Dermatology and Skin Diseases (3 papers), Osteoarthritis Treatment and Mechanisms (3 papers) and Antibiotics Pharmacokinetics and Efficacy (3 papers). The work is most often cited by research in Pharmacology (144 citations), Organic Chemistry (234 citations), Molecular Medicine (30 citations), Toxicology (20 citations) and Immunology (115 citations). John Breton has collaborated with scholars based in United States, United Kingdom and Colombia. Frequent co-authors include Marie Chabot‐Fletcher, Don E. Griswold, Jerry L. Adams, John C. Lee, Margaret E. Sorenson, Ravi S. Garigipati, Edward F. Webb, Jeffrey T. Laydon, Timothy F. Gallagher and C. Jacques. Their work appears in journals such as Journal of Investigative Dermatology, Antimicrobial Agents and Chemotherapy, Journal of Pharmacology and Experimental Therapeutics, Biochemical Journal and Biochemical Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact